IM Therapeutics is a clinical-stage company building personalized oral therapies that block disease‑associated HLA variants to treat autoimmune diseases. Its platform combines computational chemistry, bioassays and rational drug design to screen millions of compounds for optimal docking within HLA proteins. The company's lead candidate, oral IMT-002, is directed at HLA DQ8 and is being advanced through IND development for type 1 diabetes after a Phase 1b study showed inhibition of the autoimmune response in recently diagnosed, DQ8-positive patients. IM Therapeutics was founded by physician-scientists at the Barbara Davis Center for Diabetes (University of Colorado) and is expanding its HLA blockade platform to additional targets including celiac disease. Management includes CEO Nandan Padukone, and the company recently added investor representatives to its board. Financially, the company announced a $10 million Series A to advance its discovery platform and clinical program.

Total raised

$10M

Funding rounds

1

Latest round

Series A

Latest activity

Oct 2019